| Species |
Mouse |
| Protein Construction |
Fas/TNFRSF6/CD95 (Gln22-Arg169)_x000D_
Accession # P25446 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Fas Ligand, His Tag at 1μg/ml (100μl/well) on the plate can bind Fas/TNFRSF6/CD95 hFc Chimera, Mouse. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
43.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD95 (also known as Fas) is a member of the tumor necrosis factor receptor (TNFR) superfamily. Its cognate ligand, CD95L, is implicated in immune homeostasis and immune surveillance. Mutations in this receptor are associated with a loss of apoptotic signaling and have been detected in an autoimmune disorder called autoimmune lymphoproliferative syndrome (ALPS) type Ia, which shares some clinical features with systemic lupus erythematosus (SLE). |
| Synonyms |
FASLG receptor; CD95; APT1; FAS1; TNFRSF6; FAS; ALPS1A; APO1; FASTM; FasR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
